- Home
- COLA vs ACHV Comparison
COLA vs ACHV Comparison
Compare COLA & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLA
- ACHV
- Stock Information
- Founded
- COLA 2024
- ACHV N/A
- Country
- COLA Singapore
- ACHV Canada
- Employees
- COLA N/A
- ACHV N/A
- Industry
- COLA
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- COLA
- ACHV Health Care
- Exchange
- COLA NYSE
- ACHV Nasdaq
- Market Cap
- COLA 79.8M
- ACHV 72.5M
- IPO Year
- COLA 2025
- ACHV N/A
- Fundamental
- Price
- COLA $10.08
- ACHV $3.58
- Analyst Decision
- COLA
- ACHV Strong Buy
- Analyst Count
- COLA 0
- ACHV 3
- Target Price
- COLA N/A
- ACHV $14.33
- AVG Volume (30 Days)
- COLA 20.0K
- ACHV 234.9K
- Earning Date
- COLA 01-01-0001
- ACHV 05-13-2025
- Dividend Yield
- COLA N/A
- ACHV N/A
- EPS Growth
- COLA N/A
- ACHV N/A
- EPS
- COLA N/A
- ACHV N/A
- Revenue
- COLA N/A
- ACHV N/A
- Revenue This Year
- COLA N/A
- ACHV N/A
- Revenue Next Year
- COLA N/A
- ACHV N/A
- P/E Ratio
- COLA N/A
- ACHV N/A
- Revenue Growth
- COLA N/A
- ACHV N/A
- 52 Week Low
- COLA $9.95
- ACHV $1.84
- 52 Week High
- COLA $10.10
- ACHV $5.58
- Technical
- Relative Strength Index (RSI)
- COLA N/A
- ACHV 69.97
- Support Level
- COLA N/A
- ACHV $2.89
- Resistance Level
- COLA N/A
- ACHV $3.32
- Average True Range (ATR)
- COLA 0.00
- ACHV 0.25
- MACD
- COLA 0.00
- ACHV 0.06
- Stochastic Oscillator
- COLA 0.00
- ACHV 95.12
About COLA COLUMBUS ACQUISITION CORP
Columbus Acquisition Corp is a blank check company.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.